Evelo Biosciences, Inc.
NASDAQ:EVLO
0.0004 (USD) • At close November 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 78.554 | 83.643 | 69.616 | 63.128 | 39.885 | 19.957 | 9.134 |
| General & Administrative Expenses
| 29.912 | 31.753 | 22.27 | 23.229 | 18.218 | 7.574 | 3.891 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 29.912 | 31.753 | 22.27 | 23.229 | 18.218 | 7.574 | 3.891 |
| Other Expenses
| 0.061 | 0.486 | -1.371 | 1.075 | 1.157 | -0.301 | -0.02 |
| Operating Expenses
| 108.466 | 115.396 | 91.886 | 86.357 | 58.103 | 27.531 | 13.025 |
| Operating Income
| -108.466 | -115.396 | -91.886 | -86.357 | -58.103 | -27.531 | -13.025 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -5.131 | -6.352 | -1.371 | 0.885 | 1.157 | -0.301 | -0.02 |
| Income Before Tax
| -113.597 | -121.748 | -93.257 | -85.472 | -56.946 | -28.047 | -13.332 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.93 | 0.428 | 0.409 | 0.19 | -3.092 | 0.215 | 0.287 |
| Net Income
| -114.527 | -122.176 | -93.666 | -85.662 | -53.854 | -28.047 | -13.332 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.98 | -94.55 |
| EPS Diluted
| -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.55 | -94.06 |
| EBITDA
| -108.405 | -114.91 | -91.886 | -86.357 | -58.103 | -26.697 | -12.53 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |